Evidence map›Paper›PMID 41680470›Full record

ArticleExperimental & molecular medicine2026

CDK13 drives clear cell renal carcinoma through METTL16-mediated m

Jinsuo Chen, Huan Liu, Yong Zhang, Junfei Gu, Xiaoli Wu, Fan Xuan, Changbao Qu, Hao Sun, Nanxi Yue, Chenxiao Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Beyond mBiomedicines · 2026
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jinsuo Chen *Clinical Medical College, Hebei University, Department of Urology, Affiliated Hospital of Hebei University, Baoding, China.
Huan Liu *Department of Radiotherapy, The First Central Hospital of Baoding, Baoding, China.
Yong Zhang *Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Junfei GuDepartment of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Xiaoli WuDepartment of Pediatrics Hematology-Oncology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Fan XuanDepartment of Pediatrics Hematology-Oncology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Changbao QuDepartment of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China.
Hao SunDepartment of Biochemistry and Molecular Biology, The Key Laboratory of Neural and Vascular Biology, Ministry of Education of China, Hebei Medical University, Shijiazhuang, China.
Nanxi YueDepartment of Biochemistry and Molecular Biology, The Key Laboratory of Neural and Vascular Biology, Ministry of Education of China, Hebei Medical University, Shijiazhuang, China.
Chenxiao YangCenter of Tumor Immunology and Cytotherapy, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Hongye ZhaoDepartment of Biochemistry and Molecular Biology, The Key Laboratory of Neural and Vascular Biology, Ministry of Education of China, Hebei Medical University, Shijiazhuang, China.
Wenzeng YangClinical Medical College, Hebei University, Department of Urology, Affiliated Hospital of Hebei University, Baoding, China. bdywz@sina.com.
Zhan YangCenter of Tumor Immunology and Cytotherapy, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China. yangzhan@hebmu.edu.cn.ORCID http://orcid.org/0000-0001-7191-2910

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82573927National Natural Science Foundation of China (National Science Foundation of China) No. 82472667Natural Science Foundation of Hebei Province (Hebei Provincial Natural Science Foundation) NO. H2020206301Natural Science Foundation of Hebei Province (Hebei Provincial Natural Science Foundation) NO. H2023206222Taishan Scholar Project of Shandong Province tsqn202312380
6 · The paper itself

Abstract

Cyclin-dependent kinase 13 (CDK13) has emerged as a critical regulator of oncogenic metabolism, but its role in rewiring lipid metabolism in clear cell renal cell carcinoma (ccRCC) remains undefined. Here we identify CDK13 as a master orchestrator of lipid dysregulation in ccRCC, demonstrating that it drives de novo lipogenesis through a phosphorylation-dependent RNA N

Indexed as

AdenosineCarcinoma, Renal CellCDC2 Protein KinaseKidney NeoplasmsMethyltransferasesRNA, MessengerAnimalsCell Line, TumorEpitranscriptomeGene Expression Regulation, NeoplasticHumansMiceRNA MethylationAdenosineCDC2 Protein KinaseMethyltransferasesMETTL16 protein, humanN-methyladenosineRNA, Messenger

Identifiers

PMID41680470
PMCPMC12992896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.